Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Lüftner, Diana [VerfasserIn]   i
 Schütz, Florian [VerfasserIn]   i
 Schneeweiss, Andreas [VerfasserIn]   i
 Hartkopf, Andreas [VerfasserIn]   i
 Bloch, Wilhelm [VerfasserIn]   i
 Decker, Thomas [VerfasserIn]   i
 Uleer, Christoph [VerfasserIn]   i
 Stötzer, Oliver [VerfasserIn]   i
 Foerster, Frank [VerfasserIn]   i
 Schmidt, Marcus [VerfasserIn]   i
 Mundhenke, Christoph [VerfasserIn]   i
 Tesch, Hans [VerfasserIn]   i
 Jackisch, Christian [VerfasserIn]   i
 Fischer, Thomas [VerfasserIn]   i
 Kreuzeder, Julia [VerfasserIn]   i
 Guderian, Gernot [VerfasserIn]   i
 Fasching, Peter A. [VerfasserIn]   i
Titel:Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer
Titelzusatz:results from the open-label, multicentre, non-interventional BRAWO study
Verf.angabe:Diana Lüftner, Florian Schuetz, Andreas Schneeweiss, Andreas Hartkopf, Wilhelm Bloch, Thomas Decker, Christoph Uleer, Oliver Stötzer, Frank Foerster, Marcus Schmidt, Christoph Mundhenke, Hans Tesch, Christian Jackisch, Thomas Fischer, Julia Kreuzeder, Gernot Guderian, Peter A. Fasching
E-Jahr:2024
Jahr:1 July 2024
Umfang:11 S.
Illustrationen:Illustrationen
Fussnoten:Zuerst veröffentlicht: 06. März 2024 ; Gesehen am 23.08.2024
Titel Quelle:Enthalten in: International journal of cancer
Ort Quelle:Bognor Regis : Wiley-Liss, 1966
Jahr Quelle:2024
Band/Heft Quelle:155(2024), 1 vom: Juli, Seite 128-138
ISSN Quelle:1097-0215
Abstract:BRAWO, a real-world study, assessed the efficacy, quality of life (QoL) and safety of EVE + EXE in postmenopausal women with HR+/HER2- advanced breast cancer (ABC) in routine clinical practice. Postmenopausal women with HR+/HER2-ABC with recurrence or progression after a NSAI were included. Primary Observation parameters included the evaluation of the effectiveness of EVE + EXE. A multivariate-analysis using Cox proportional hazard model was built to identify predictors of progression. Overall, 2100 patients were enrolled (August 2012-December 2017); 2074 were evaluable for efficacy and safety analyses. Majority of patients (60.6%) received EVE + EXE as first (28.7%) or second-line (31.9%) therapy. Visceral metastases were present in 54.1% patients. Median progression-free survival (mPFS) reported as 6.6 months (95%CI: 6.3-7.0). Multivariate-analysis in a subset of patients (n = 1837) found higher body mass index (BMI) and non-visceral metastases to be independent predictors of favorable PFS. Patients with a BMI of 20 to <25 had a mPFS of 6.0 (95%CI: 5.4-6.4) and those with a BMI ≥30 had mPFS of 8.5 (95%CI: 6.9-9.9). 41.2% patients achieved stable disease and 7.3% partial response. No major changes were observed QoL; 86.4% patients received stomatitis prophylaxis and 41.4% experienced EVE related AEs of stomatitis, mainly low grade. AEs occurred in 91.2% of patients, of which stomatitis (42.6%) and fatigue (19.8%) were most frequent. The BRAWO study provides real-world evidence of efficacy and safety of EVE + EXE in patients with HR+, HER2− ABC. A high BMI and the absence of visceral metastases were independent predictors of PFS in this cohort of patients.
DOI:doi:10.1002/ijc.34912
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1002/ijc.34912
 Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.34912
 DOI: https://doi.org/10.1002/ijc.34912
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:advanced breast cancer
 everolimus
 exemestane
 HER2-
 HR+
K10plus-PPN:1899439382
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69246578   QR-Code
zum Seitenanfang